Ruoslahti E. Integrins. J Clin Invest, 1991, 87, 1-5.
Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994, 264, 569-571.
Reardon DA, Cheresh D. Cilengitide : A prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer, 2011, 2, 1159-1165.
Gaertner FC, Kessler H, Wester HJ, et al. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging, 2012, 39, S126-138.
Zhang X, Xiong Z, Wu Y, et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med, 2006, 47, 113-121.
Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res, 2006, 12, 3942-3949.
Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol, 2009, 11, 861-870.
Wan W, Guo N, Pan D, et al. First experience of 18F-Alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med, 2013, 54, 691-698.
Desgrosellier JS, Barnes LA, Shields DJ, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med, 2009, 15, 1163-1169.
Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res, 2005, 11, 6270-6279.
Seguin L, Kato S, Franovic A, et al. An integrin beta-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol, 2014, 16, 457-468.
Thonon D, Goblet D, Goukens E, et al. Fully automated preparation and conjugation of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) with RGD peptide using a GE FASTlab synthesizer. Mol Imaging Biol, 2011, 13, 1088-1095.
Withofs N, L?onard M, Aerts J, et al. [18F]FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas : Correlation with histopathology. J Nucl Med, 2012, 53, 1647.
Withofs N, Scagnol I, Thonon D, et al. Preliminary results of [18F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. J Nucl Med, 2012, 53, 1703.
Edge SB, Compton CC, Fritz AG, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer., 2010.
Withofs N, Simoni P, Luxen A, et al. Imaging osteoarthritis and periarticular bone changes using [18F]FPRGD2 PET/CT : Observation and potential application. J Nucl Med, 2013, 54, 250.
Zheleznyak A, Wadas TJ, Sherman CD, et al. Integrin alpha(v)beta(3) as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol, 2012, 14, 500-508.
Sherif HM, Saraste A, Nekolla SG, et al. Molecular imaging of early alphavbeta3 integrin expression predicts long-Term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med, 2012, 53, 318-323.
Beer AJ, Pelisek J, Heider P, et al. PET/CT Imaging of Integrin alphavbeta3 Expression in Human Carotid Atherosclerosis. JACC Cardiovasc Imaging, 2014, 7, 178-187.
Tegler G, Estrada S, Hall H, et al. Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms. Ups J Med Sci, 2014, 119, 229-235.
